Kidney Transplantation Clinical Trial
Official title:
A Prospective Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection According to Baseline hCMV-specific T-cell Response in Kidney Transplant Patients (RESPECT)
The aim of this prospective, randomized study is to assess a subject's immunological status against hCMV before kidney transplantation by an hCMV-specific interferon (INF)-γ ELISPOT technique confirming previous results and establishing their statistical validity in order to determine whether this test could be used routinely in clinical practice to assess the risk of developing hCMV infection after renal transplantation and, ultimately, identify the most effective individual antiviral therapeutic strategy against hCMV.
Human cytomegalovirus (hCMV) is the most common opportunistic pathogen in the first months
after solid organ transplantation. Traditionally, hCMV infection in renal transplant patients
is indirectly associated with an increased risk of acute rejection, chronic graft
dysfunction, graft loss and even increased patient mortality.
The susceptibility of developing hCMV infection is essentially determined by the immune
status of the donor and the receptor with regards to the virus, whereby seronegative
recipients (IgG) receiving a graft from a seropositive donor (IgG +) are the group of
patients with a particularly high risk for developing hCMV infection and disease. In fact,
without the administration of a preventative therapy for hCMV, 60 to 70% of this population
at risk have an infection (presence of virus in the blood) and up to approximately 20% will
develop associated systemic disease (viral invasion of tissues ). Interestingly, the
incidence of hCMV infection in patients who are seropositive for the HIV virus and receive a
graft is about 20%, increasing to 30% if given cell depletion therapies with polyclonal
antibodies administered after transplantation.
There are currently two treatment options to prevent infection by hCMV; One is prophylactic,
whereby the antiviral therapy is administered orally for about 90 to 100 days after
transplantation in all patients considered at risk (donor IgG+, recipient IgG-) and the
second is pre-emptive therapy, in which the presence of virus in the peripheral blood is
monitored periodically after transplantation until it appears (at present by polymerase chain
reaction (PCR) detection of viral nucleic acids),thus triggering the need for intensive
antiviral therapy. When compared with no pharmacological intervention, both therapeutic
strategies have demonstrated a significant reduction in the development of hCMV and other
herpes virus type diseases, and even a decrease in the incidence of acute graft rejection.
However, there are few prospective randomized studies comparing the effectiveness of these
two therapeutic alternatives. Recently, a German group prospectively compared the efficacy of
prophylactic oral ganciclovir versus intravenous ganciclovir therapy in a group of 148
patients receiving high serological risk renal transplants for hCMV. Interestingly, the group
that received prophylactic oral therapy had a higher graft survival at 4 years of follow up
(uncensored for death) than the group receiving ganciclovir, suggesting that, despite the
administration of intensive intravenous therapy at the time of detection of the virus in the
blood, the potential deleterious effect of the virus on the organs during the initial
asymptomatic period could explain the benefits of prophylactic therapy from the beginning.
These results have important implications, both clinical and socioeconomic, as they seem to
imply the need for systemic prophylaxis to prevent the development of viral infection in all
patients currently considered at risk (R -/D +). Moreover, another interesting study which
compared primary prophylaxis with oral valganciclovir versus early therapy prevention
(pre-emptive therapy) in a large group of kidney transplant recipients with different
serologic donor / recipient combinations, showed significantly higher rates of viremia and
CMV disease in patients receiving treatment with an incidence of serological CMV infection of
up to 53% in serological R + / R + combinations. In this sense, the latest international
consensus guidelines indicate that both types of therapy (early and prophylactic) are
acceptable, with a degree of moderately high evidence, for groups of seropositive patients
receiving a graft from a seropositive donor. The investigator unit has adopted a pre-emptive
protocol for the last two years, systematically monitoring viral replication in R + / D +
pairs, except in those patients receiving immunosuppressive therapy with Thymoglobulin to
whom the investigator assigns a prophylactic treatment with oral valganciclovir for 3
months.This change was introduced 2 years ago before which a prophylactic treatment was given
to all R + / R + patients. This change has not led to improved results in terms of prevention
of cytomegalic infection.
All such discrepancies among study results examining the efficacy of various therapeutic
strategies preventing hCMV could be explained by the poor diagnostic capabilities currently
available to identify those patients truly at high risk of developing cytomegalic infection.
This is illustrated by the fact that hCMV infection reappears in some patients (15-20%) after
transplantation even though they are seropositive (R+) and that, while the majority of
patients receiving prophylactic treatment never develop cytomegalic infection after its
discontinuation, a small percentage (10-15%) still does, and that, even though 70-80% of
seronegative (R-) patients receiving a seropositive graft (R+) will develop post-transplant
hCMV infection unless they receive prophylactic treatment, approximately 20-30% never will.
All of this leads to important therapeutic contradictions in this field such as that, even
though the majority of seropositive recipients will not develop hCMV infection, all of them
will still receive an intense and costly monitoring for viremia, and that, although a large
majority of patients receiving prophylactic treatment will not develop infection upon
treatment discontinuation, continuing such prophylactic antiviral treatment is being proposed
across the clinical transplantation community, suggesting that immune surveillance of the
risk of developing a post-transplant hCMV infection is currently very poor in clinical
practice. It is well established that memory/effector T-cells play a pivotal role in
controlling general viral replication and survival, particularly for hCMV. Even though it has
been reported that cytotoxic CD8+ T-cells can be activated by a myriad of immunogenic hCMV
viral proteins, the predominant and most robust response is directed at the immediate early
antigen-1 (IE-1) and phosphoprotein 65 (pp65), which is thought to play a critical role in
controlling hCMV replication. Recently published studies suggest that such cellular response
is even important for the control and prevention of infection after transplantation.
All such publications, however, refer to the post-transplantation period while patients are
under the effects of chronic immunosuppressive therapy and evaluate the T-cell response using
assays hardly applicable to routine clinical practice. Even though available, such assays are
not used in routine clinical practice to evaluate the hCMV-specific immune response.
One of the most precise functional assays to assess both memory cell and humoral responses
under evaluation is the interferon-γ ELISPOT assay. This assay measures antigen-specific
memory response frequency by individual cells as they become stimulated.
Recent work in transplantation has established that the detection of highly alloreactive
circulating donor-specific T-cells by ELISPOT offers prognostic value when assessing the risk
of acute rejection or chronic post-transplant graft dysfunction. Likewise, ELISPOT has been
shown to be able to detect highly reactive hCMV-specific T-cells associated with a lower risk
of viral infection with both sensitivity and specificity.
The investigator group has recently published that low frequency rates of specific hCMV
(IE-1) T-cells before transplantation identify renal transplant recipients at a higher risk
of post-transplant hCMV infection with precision, regardless of the therapeutic strategy
adopted against hCMV. Remarkably, the same results were observed in patients receiving
induction therapy with polyclonal antibodies (Thymoglobuline ®). The investigator thus
believes that such an assay approach would allow to identify with precision those patients at
risk of developing an infection regardless of their hCMV serology status.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT02723591 -
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT05945511 -
Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
|
||
Completed |
NCT02234349 -
Bile Acids and Incretins in Pancreas Kidney Transplant Patients
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT05934383 -
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
|
N/A | |
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Not yet recruiting |
NCT04540640 -
Oxygenated Machine Preservation in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Completed |
NCT02560558 -
Bela 8 Week Dosing
|
Phase 4 | |
Terminated |
NCT02417870 -
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02154815 -
Pre-emptive Kidney Transplantation Quality of Life
|
N/A | |
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Enrolling by invitation |
NCT01905514 -
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
|
N/A | |
Completed |
NCT02147210 -
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
|
N/A | |
Recruiting |
NCT01699360 -
The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 |